These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2597555)

  • 1. A novel approach to anticoagulation control.
    Kim JS; Vincent C; Teng CL; Wakefield TW; Yang VC
    ASAIO Trans; 1989; 35(3):644-6. PubMed ID: 2597555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A protamine filter for extracorporeal blood heparin removal.
    Teng CL; Kim JS; Port FK; Wakefield TW; Till GO; Yang VC
    ASAIO Trans; 1988; 34(3):743-6. PubMed ID: 3196594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A filter device for the prevention of both heparin- and protamine-induced complications associated with extracorporeal therapy.
    Yang VC; Teng CL; Kim JS
    Biomed Instrum Technol; 1990; 24(6):433-9. PubMed ID: 2261582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of immobilized protamine in removing heparin and preventing protamine-induced complications during extracorporeal blood circulation.
    Yang VC; Port FK; Kim JS; Teng CL; Till GO; Wakefield TW
    Anesthesiology; 1991 Aug; 75(2):288-97. PubMed ID: 1859016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A protamine filter for extracorporeal heparin removal. Development, testing, blood compatibility evaluation, and future direction.
    Byun Y; Yun JH; Han IS; Fu Y; Shanberge JN; Yang VC
    ASAIO J; 1995; 41(3):M301-5. PubMed ID: 8573812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for improving the functionality of an affinity bioreactor.
    Wang T; Yang Z; Emregul E; David A; Balthasar JP; Liang J; Yang VC
    Int J Pharm; 2005 Dec; 306(1-2):132-41. PubMed ID: 16246511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of hemodynamic and hematologic effects of heparin-protamine sulfate interaction after aortic reconstruction in a canine model.
    Wakefield TW; Lindblad B; Whitehouse WM; Hantler CB; Stanley JC
    Surgery; 1986 Jul; 100(1):45-51. PubMed ID: 3726760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model.
    Lee LM; Chang LC; Wrobleski S; Wakefield TW; Yang VC
    AAPS PharmSci; 2001; 3(3):E19. PubMed ID: 11741270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel protamine variant reversal of heparin anticoagulation in human blood in vitro.
    Hulin MS; Wakefield TW; Andrews PC; Wrobleski SK; Stoneham MD; Doyle AR; Zelenock GB; Jacobs LA; Shanley CJ; TenCate VM; Stanley JC
    J Vasc Surg; 1997 Dec; 26(6):1043-8. PubMed ID: 9423721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel approach for optimizing the capacity and efficacy of a protamine filter for clinical extracorporeal heparin removal.
    Zhang Y; Singh VK; Yang VC
    ASAIO J; 1998; 44(5):M368-73. PubMed ID: 9804453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement depletion and persistent hemodynamic-hematologic responses in protamine-heparin reactions.
    Wakefield TW; Till GO; Lindblad B; Saenz N; Stanley JC
    J Surg Res; 1988 Sep; 45(3):320-6. PubMed ID: 3411956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of a heparin removal device: a valid alternative to protamine.
    Hendrikx M; Leunens V; Vandezande E; Wallyn A; Flameng W
    Int J Artif Organs; 1997 Mar; 20(3):166-74. PubMed ID: 9151153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulant effects of protamine sulfate in a canine model.
    Kresowik TF; Wakefield TW; Fessler RD; Stanley JC
    J Surg Res; 1988 Jul; 45(1):8-14. PubMed ID: 3392995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous venovenous hemofiltration without anticoagulation.
    Uchino S; Fealy N; Baldwin I; Morimatsu H; Bellomo R
    ASAIO J; 2004; 50(1):76-80. PubMed ID: 14763495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study.
    Fabbri LP; Nucera M; Al Malyan M; Becchi C
    Acta Anaesthesiol Scand; 2010 Jan; 54(1):92-7. PubMed ID: 19650808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protamine-coated Cuprophan. A potential nonthrombogenic hemodialysis membrane with improved blood compatibility.
    Yang VC; Fu YY; Kim JS
    ASAIO Trans; 1991; 37(3):M229-32. PubMed ID: 1751122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the hemodynamic and hematologic toxicity of a protamine variant after reversal of low-molecular-weight heparin anticoagulation in a canine model.
    Hulin MS; Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Downing LJ; Stanley JC
    Lab Anim Sci; 1997 Apr; 47(2):153-60. PubMed ID: 9150494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization and assessment of the in vivo efficacy of a heparin removing bio-reactor using mathematical modeling.
    Byun Y; Wang T; Kim JS; Yang VC
    ASAIO J; 1996; 42(5):M782-7. PubMed ID: 8944989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of complement-mediated events after protamine reversal of heparin anticoagulation.
    Wakefield TW; Kirsh MM; Till GO; Brothers TE; Hantler CB; Stanley JC
    J Surg Res; 1991 Jul; 51(1):72-6. PubMed ID: 2067362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of protamine hollow-fiber device for extracorporeal heparin removal.
    Liang JF; Emregul E; Yang VC
    Blood Purif; 2004; 22(2):198-202. PubMed ID: 15044818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.